Novartis weighs major investment in Denton manufacturing plant
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
Swiss-based Novartis is considering a $280 million investment to build a new manufacturing plant in Denton that would support advanced pharmaceutical production and create high wage jobs. The proposal, still under review, could bring a significant expansion of Novartis’ presence in the United States and strengthen the local economy.
The company has identified a 20 acre site at 2101 Shady Oaks Drive that has been unused since 2009 when US Radiopharmaceuticals ceased operations there. The existing location includes about 50,000 square feet of space, and it is owned by Kensington Title Nevada LLC. Novartis has not confirmed its plans publicly and declined to comment, even as the city of Denton prepares to discuss tax incentives.
Denton incentives and state support aim to seal the deal
Novartis plans to use the site for the manufacture of radioligand therapy pharmaceuticals, a form of precision cancer care that combines a tumor targeting molecule with a therapeutic radioactive agent. This class of treatment has grown in prominence because it can deliver targeted radiation while limiting damage to surrounding tissue and healthy cells. The custom nature of each dose and the short life of the radioactive materials make geographic closeness to treatment centers and transportation hubs an important factor in ensuring timely delivery to patients.
The Denton City Council will hear public comment on an incentives package worth over $3 million, including a 10 year tax abatement valued at more than $2 million, rebates on sales tax for construction material purchases and grants tied to job creation and site cleanup. The project also has a pending unspecified grant from the Texas Enterprise Fund and state property tax exemptions estimated at about $5.9 million over the coming decade.
Cleanup of the Shady Oaks site is a priority because it was previously used for radiopharmaceutical purposes and contains hazardous materials. A presentation prepared for the city shows the first phase of the project would involve removing these materials and preparing the existing buildings for Novartis’ innovative manufacturing processes. The interior of the structures will be upgraded, and a secure containment facility will be installed to handle radioactive materials safely.
National strategy drives regional investment
Novartis’ plans reflect a broader strategy to expand its US manufacturing footprint. In April the company announced a $23 billion investment over five years aimed at expanding manufacturing and research and development operations in the US. This expansion involves ten facilities and could generate about 1,000 direct jobs at Novartis and nearly 4,000 additional jobs across the economy. Part of this investment includes planned radioligand therapy facilities in Florida and Texas, as well as upgrades to existing sites in states such as California, Indiana and New Jersey.
The addition of a manufacturing plant in Denton would add to this broader effort to localize production within the US. This trend has gained momentum as companies seek to bring production closer to patients, strengthen supply chains and respond to a changing policy environment that encourages domestic manufacturing of critical medicines. US based manufacturing can also improve resiliency against supply disruptions and support faster delivery of time sensitive therapies.
High paying jobs and long term economic returns
The jobs expected from the Denton plant would focus on technical roles and pay well above local averages. Novartis projects at least 150 new jobs with an average salary of more than $124,000, which could have a positive multiplier effect on the region’s economy. Local governments are counting on this employment impact to justify the incentives being offered to secure the project.
City estimates suggest that after about three years the incentives package will begin to generate returns for the public sector. Over a ten year period, the city expects to collect $4.8 million from tax revenues tied to the facility. In addition to benefits for the city, the county and local school district would see increased tax receipts, while the transit district would also benefit from added revenue.
Community interest in the project is significant, with a public hearing scheduled that will allow residents and business leaders to weigh in on the incentives and the broader implications of the investment. The Texas Enterprise Fund has been used by the state to attract a range of companies to invest in high wage industries, and the outcome of the Denton City Council’s decision will signal the level of local support for this type of manufacturing growth.
Novartis is one of the largest pharmaceutical companies in the world and has pursued acquisitions and partnerships to strengthen its capabilities in areas such as cancer treatment and advanced therapies. The company’s decision to expand its footprint in the US reflects a long running effort to align production with demand in one of the world’s largest markets for medicines.
If approved and constructed, the Denton manufacturing plant could become a key part of this national strategy and bring both economic and scientific investment to North Texas. The future of the site will depend on the outcome of city and state deliberations on incentives, as well as Novartis’ final decision on how to allocate part of its broad manufacturing expansion in the US economy.
Sources